Cefuroxime Axetil For Oral Suspension

Product NDC: 63304-963
11-digit product format: 633040963
Labeler code: 63304
Product ID: 63304-963_037e5290-f39e-45ef-a05c-51b0ce2c4473
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Cefuroxime Axetil
Dosage form: SUSPENSION
Route: ORAL
Labeler: Ranbaxy Pharmaceuticals Inc
Application: ANDA065323
Marketing category: ANDA
Marketing start: 2008-02-08
Marketing end: 0000-00-00
Substance: CEFUROXIME AXETIL
Active strength: 125 mg/5mL
Pharmacologic classes: Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag: E
Listing certified through: 2017-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	63304-963		I	Inactivated by FDA	2026-10-15
excluded package	package	63304-963	63304-963-03	I	Inactivated by FDA	2026-10-15
excluded package	package	63304-963	63304-963-04	I	Inactivated by FDA	2026-10-15

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 2 · 66 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	63304-963-04	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	63304-963-03	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	63304-963-04	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	63304-963-03	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	63304-963-04	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	63304-963-03	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	63304-963-04	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	63304-963-03	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	63304-963-04	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	63304-963-03	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	63304-963-04	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	63304-963-03	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	63304-963-04	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	63304-963-03	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	63304-963-04	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	63304-963-03	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	63304-963-04	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	63304-963-03	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	63304-963-04	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	63304-963-03	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	63304-963-04	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	63304-963-03	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	63304-963-04	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	63304-963-03	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	63304-963-04	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	63304-963-03	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	63304-963-04	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	63304-963-03	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	63304-963-04	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	63304-963-03	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	63304-963-04	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	63304-963-03	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	63304-963-04	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	63304-963-03	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	63304-963-04	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	63304-963-03	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	63304-963-04	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	63304-963-03	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	63304-963-04	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	63304-963-03	`e2bbac7714bc…`	`27bdfed8d636…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
A065323-001	CEFUROXIME AXETIL	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL			2008-02-05
A065323-002	CEFUROXIME AXETIL	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL			2008-02-05

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	A065323-001	CEFUROXIME AXETIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	A065323-002	CEFUROXIME AXETIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2008-02-05	`4b0b4de00fa7…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
362d7abb-94e6-4c60-9a58-266894157713	Product name	1	20231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ce	Product name	2	20230315
c6f86816-7da6-43ea-8c25-ac9758311cc5	Product name	1	20220118
f1e0dc7e-7d61-4625-b6d9-4894927679d7	Product name	2	20211025
a62a50ac-1535-4461-9768-8ae703e2e9fb	Product name	1	20210525
e4870509-7e28-6f92-f0be-dd3dd889a9cf	Product name	5	20200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cd	Product name	2	20190619
444b3e50-f226-46ef-bfca-2e7035d140cd	Product name	1	20190611
816b97af-edc5-4060-aff1-b814bdbcad50	Product name	1	20190415
7cda52fc-125f-421c-8fea-bc1974370c49	Product name	2	20180703
252e11b6-1a9a-4283-a242-df2c129c496d	Product name	3	20170717
419aab54-5d5a-4146-9453-026d4a9991be	Product name	2	20170525
d5e51f11-ad28-caa4-4b49-4143974782ad	Product name	1	20150831
290f523a-f9db-9774-b5a9-e1f908ac1782	Product name	1	20150828
89dac932-b90a-4410-9ab1-84c53e57de25	Product name	1	20150316
5668b646-cd56-c3c7-bdea-3f6b1a8840db	Product name	1	20140508
684ea482-2e8b-14af-5664-b98f1e402036	Product name	1	20140508
810ab97e-f109-f41c-7c83-6a652a9cbf43	Product name	1	20140508
87711080-88eb-65c5-b2dd-bf99e700a372	Product name	1	20140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2dd	Product name	1	20140508
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877	Product name	1	20140508
b060cc1a-fe47-856b-0b77-4448b5963de8	Product name	1	20140508
ba66f2a7-7ba5-e81a-8863-a38bd5c2e969	Product name	1	20140508
bc07ef78-e82d-0c19-31f4-31f263780582	Product name	1	20140508
c6b65c52-69c7-df49-550a-a50c137f6218	Product name	1	20140508
ec2149b3-5c6d-5344-f757-c86411073075	Product name	1	20140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
63304-963-03	2019-11-27	C162847	48780-1	9855d018-ecb7-cd31-e053-dbdaa90ab51a	CEFUROXIME AXETIL FOR ORAL SUSPENSION,USP Rx Only
63304-963-04	2019-11-27	C162847	48780-1	9855d018-ecb7-cd31-e053-dbdaa90ab51a	CEFUROXIME AXETIL FOR ORAL SUSPENSION,USP Rx Only

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
63304-963-03	Cefuroxime Axetil For Oral Suspension	50 mL in 1 BOTTLE	SUSPENSION	50		1
63304-963-04	Cefuroxime Axetil For Oral Suspension	100 mL in 1 BOTTLE	SUSPENSION	100		1

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
63304-963-04	ML - Milliliter	63304-963	c6afb343-1afc-476f-aace-784964e43540	1	2013-09-04

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CEFUROXIME AXETIL	ACTIVE INGREDIENT	Z49QDT0J8Z	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
CEFUROXIME	ACTIVE MOIETY	O1R9FJ93ED	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
ASPARTAME	INACTIVE INGREDIENT	Z0H242BBR1	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)	INACTIVE INGREDIENT	87Y6436BKR	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
MANNITOL	INACTIVE INGREDIENT	3OWL53L36A	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)	INACTIVE INGREDIENT	74G4R6TH13	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
MONOSODIUM CITRATE	INACTIVE INGREDIENT	68538UP9SE	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
SODIUM CHLORIDE	INACTIVE INGREDIENT	451W47IQ8X	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
SUCROSE	INACTIVE INGREDIENT	C151H8M554	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
63304-963	CEFUROXIME AXETIL FOR ORAL SUSPENSION (CEFUROXIME AXETIL) SUSPENSION [RANBAXY PHARMACEUTICALS INC]	1	Legacy NDC, 2 package rows	20130821_135e2dfc-eb47-4d04-a903-a081d36c267e.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
Z49QDT0J8Z	CEFUROXIME AXETIL	64544-07-6	CEFUROXIME AXETIL

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
309096	cefuroxime axetil 125 MG in 5 mL Oral Suspension	PSN	135e2dfc-eb47-4d04-a903-a081d36c267e	1
309096	cefuroxime 25 MG/ML Oral Suspension	SCD	135e2dfc-eb47-4d04-a903-a081d36c267e	1
309096	cefuroxime axetil 125 MG per 5 ML Oral Suspension	SY	135e2dfc-eb47-4d04-a903-a081d36c267e	1

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Status
63304-963-03	63304096303	50 mL in 1 BOTTLE	50 ml	Historical
63304-963-04	63304096304	100 mL in 1 BOTTLE	100 ml	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
CEFUROXIME AXETIL FOR ORAL SUSPENSION,USP Rx Only	Ranbaxy Pharmaceuticals Inc \| RANBAXY LABORATORIES LIMITED - DEWAS	2013-08-19	HUMAN PRESCRIPTION DRUG LABEL	1